LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals

November 18, 2025 updated by: baoguanai, Zhejiang Cancer Hospital

Researchers will use LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine and Plasma in Healthy Individuals

Participants will:

  • Take 3 grams of American Ginseng powder every day for 14 days
  • Collect the fasting urine samples at the following times at the hospital: On the first day, on the 7th day after taking the medicine, and on the 14th day after taking the medicine.
  • Collect the fasting Serum samples at the following times at the hospital: On the first day and on the 14th day after taking the medicine.
  • Have their any adverse effects monitored and evaluated throughout the study.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Recruiting
        • Zhejiang Cancer Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

  • 18 to 45 years old;

    • The subjects were fully informed about the research process and signed the informed consent form (the subjects had no abnormalities in routine physical examinations, no previous medical history, and no history of drug allergies); ③ During the trial, they were required to have a light diet and were prohibited from consuming alcoholic and caffeinated beverages;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: American Ginseng group
All the subjects took 3 grams of American ginseng half an hour after breakfast every day for 14 consecutive days.
Other: American Gginseng
All the subjects took 3 grams of ginseng half an hour after breakfast every day for 14 consecutive days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urine metabolomics
Time Frame: From enrollment to the end of treatment at 2 weeks
By using LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine in Healthy Individuals
From enrollment to the end of treatment at 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma metabolomics
Time Frame: From enrollment to the end of treatment at 2 weeks
By using LCMS Metabolic Analysis to Explore the Effect of American Ginseng on plasma in Healthy Individuals.
From enrollment to the end of treatment at 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhejiang Cancer Hospital

Investigators

  • Study Director: guan ai Bao, Master, Zhejiang Cancer Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2023

Primary Completion (Estimated)

December 30, 2025

Study Completion (Estimated)

March 30, 2026

Study Registration Dates

First Submitted

November 18, 2025

First Submitted That Met QC Criteria

November 18, 2025

First Posted (Actual)

November 26, 2025

Study Record Updates

Last Update Posted (Actual)

November 26, 2025

Last Update Submitted That Met QC Criteria

November 18, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2021KY577

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe